Infensa Bioscience is a clinical-stage biotechnology company developing novel therapies aimed at reducing tissue and joint damage in conditions such as heart attack, acute kidney injury, organ transplant, rheumatoid arthritis, osteoarthritis, and stroke.

The lead candidate (IB409) is a blocker of Acid-Sensing Ion Channel 1a (ASIC1a), which is a genetically validated “cell death switch” activated by acidic environments and responsible for toxic calcium influx as well as activation of necroptotic cell death pathways.

IB409 is a potent (500 pM), highly selective ASIC1a inhibitor with robust preclinical results across multiple species (mouse, rat, sheep, pig) and disease models. The candidate has now entered Phase 1 clinical trials.